Our Hong Kong Foundation released the latest report (30/11) on "Developing Hong Kong into Asia's Leading Clinical Innovation Hub" to promote Hong Kong as a leading clinical research hub in Asia.

Victor Kwok, Assistant Research Director of OHKF, presented the research's top-line findings. He stated that clinical trial, as an important part in the drug development process, can bring about multiple benefits.

In addition, he pointed out that building primary review authority would help make Hong Kong a “super connector” for drug development bridging Mainland China and the vast market of the global drugs, and according to the proposed roadmap, it is expected to take up to 8 to 10 years to achieve a full primary review system.